InMed Pharmaceuticals (INM) Equity Ratio (2020 - 2026)

InMed Pharmaceuticals has reported Equity Ratio for 7 years, with the latest figure at 0.75 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio changed 0.28% year-over-year to 0.75; the trailing twelve-month figure through Mar 2026 stood at 0.75 (changed 0.28% YoY), and the FY2025 full-year result was 0.86, up 10.74% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.75, down from 0.86 in the prior quarter.
• The five-year high for Equity Ratio was 0.87 in Q3 2025, with the low at 0.88 in Q3 2023.
• Historically, Equity Ratio has averaged 0.7 across 5 years, with a median of 0.8 in 2024.
• Annual changes were most pronounced in 2023 — Equity Ratio tumbled 216.24% — and 2024, when it jumped 191.44%.
• InMed Pharmaceuticals' Equity Ratio stood at 0.85 in 2022, then fell by 1.18% to 0.84 in 2023, then fell by 13.15% to 0.73 in 2024, then climbed by 17.82% to 0.86 in 2025, then dropped by 11.92% to 0.75 in 2026.
• The last three Equity Ratio figures came in at 0.75 (Q1 2026), 0.86 (Q4 2025), and 0.87 (Q3 2025), per Business Quant data.